These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12447798)

  • 1. [Models of drug treatment in the attention deficit disorder with hyperactivity].
    Etchepareborda MC
    Rev Neurol; 2002 Feb; 34 Suppl 1():S98-S106. PubMed ID: 12447798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New therapeutic options in the treatment of attention deficit/hyperactivity disorder].
    Artigas Pallares J
    Rev Neurol; 2004 Feb; 38 Suppl 1():S117-23. PubMed ID: 15011165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Basics of the drug therapy for attention deficit hyperactivity disorders in adolescents].
    Airaksinen E; Airaksinen MM
    Duodecim; 2003; 119(16):1553-62. PubMed ID: 14535028
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnosis and management of adult attention-deficit/hyperactivity disorder.
    Post RE; Kurlansik SL
    Am Fam Physician; 2012 May; 85(9):890-6. PubMed ID: 22612184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attention deficit hyperactivity disorder. Epidemiologic, pathophysiologic, diagnostic and treatment perspectives.
    Al-Ghamdy YS; Qureshi NA
    Saudi Med J; 2001 Aug; 22(8):666-73. PubMed ID: 11573110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing comorbidity in adults with attention-deficit/hyperactivity disorder.
    Hornig M
    J Clin Psychiatry; 1998; 59 Suppl 7():69-75. PubMed ID: 9680055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms.
    Stahl SM
    J Clin Psychiatry; 2010 Mar; 71(3):223-4. PubMed ID: 20331927
    [No Abstract]   [Full Text] [Related]  

  • 9. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy.
    Noorbala AA; Akhondzadeh S
    Arch Iran Med; 2006 Oct; 9(4):374-80. PubMed ID: 17061613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mechanism of action of drugs used to treat attention-deficit hyperactivity disorder: focus on catecholamine receptor pharmacology.
    Shenker A
    Adv Pediatr; 1992; 39():337-82. PubMed ID: 1359740
    [No Abstract]   [Full Text] [Related]  

  • 12. Coming into focus. Pharmacologic treatment for ADHD.
    McDonnell MA; Moffett C
    Adv NPs PAs; 2010 Dec; 1(4):16-22; quiz 23. PubMed ID: 21319448
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of attention-deficit-hyperactivity disorder.
    Elia J; Ambrosini PJ; Rapoport JL
    N Engl J Med; 1999 Mar; 340(10):780-8. PubMed ID: 10072414
    [No Abstract]   [Full Text] [Related]  

  • 14. [Towards an understanding of the molecular mechanisms underlying the pharmacological treatments of attention deficit hyperactivity disorder].
    Castellanos FX; Acosta MT
    Rev Neurol; 2011 Mar; 52 Suppl 1():S155-60. PubMed ID: 21365598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder.
    Bond DJ; Hadjipavlou G; Lam RW; McIntyre RS; Beaulieu S; Schaffer A; Weiss M;
    Ann Clin Psychiatry; 2012 Feb; 24(1):23-37. PubMed ID: 22303520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated pharmacologic treatment of attention-deficit hyperactivity disorder (ADHD).
    Horst RO; Hendren RL
    Essent Psychopharmacol; 2005; 6(5):250-61. PubMed ID: 16222910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of psychotropic drugs in epilepsy: what every neurologist should know.
    Kanner AM
    Semin Neurol; 2008 Jul; 28(3):379-88. PubMed ID: 18777484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adderall and other drugs for attention-deficit/hyperactivity disorder.
    Med Lett Drugs Ther; 1994 Nov; 36(936):109-10. PubMed ID: 7968783
    [No Abstract]   [Full Text] [Related]  

  • 19. [Attention deficit hyperactivity disorder and epilepsy].
    Mulas F; Téllez de Meneses M; Hernández-Muela S; Mattos L; Pitarch I
    Rev Neurol; 2004 Jul 16-31; 39(2):192-5. PubMed ID: 15264172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug therapy in the treatment of minimal brain dysfunction.
    Saccar CL
    Am J Hosp Pharm; 1978 May; 35(5):544-52. PubMed ID: 26219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.